Slide 1: Inspiring the World to Move Well - Investor Update
For personal use only INSPIRING THE WORLD TO MOVE WELL INVESTOR UPDATE July 2018
Slide 2: Disclaimer
// 2 DISCLAIMER This presentation does not constitute investment, legal, taxation or other advice and the For personal use only presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusio
Slide 3: Investment Highlights
// 3 INVESTMENT HIGHLIGHTS • First mover advantage, leader with medical grade wearable technology – FDA, CE Mark, TGA approved For personal use only • Two attractive markets – Workplace and Clinical • Across three geographic markets – US, UK and Australia • Actively pursuing strategic opportunities
Slide 4: One Platform, Two Key Markets
// 4 ONE PLATFORM, TWO KEY MARKETS • Patent protected algorithms on WORKPLACE For personal use only medical-grade sensor technology • OHS solution to determine, measure and mitigate high risk • Significant barriers to entry and activities limited competition with FDA • Executive and board-level focu
Slide 5: Financial Overview FY18
// 5 FINANCIAL OVERVIEW FY18 YTD Q3 2015 2016 2017 FY18* For personal use only Revenue 1,358,218 3,019,928 3,466,027 3,433,000 EBITDA (8,851,345) (5,928,797) (4,691,358) N/A Loss from continuing (8,036,161) (5,237,102) (3,876,248) N/A operations Cash position $5.74M $6.03M $8.61M $3.97M * unaudited
Slide 6: FY18 Q4 Milestones
// 6 FY18 Q4 MILESTONES For personal use only APRIL 2018 Expansion of Mizuno Running Solution program. First sale of small sensors incorporating movement and EMG to Curtain University (100 devices). MAY 2018 AIG insurance deal for 60 ViSafe assessments over 2 years. JUNE 2018 Professional Suite laun
Slide 7: Business Evolution to Drive Scale
// 7 BUSINESS EVOLUTION TO DRIVE SCALE For personal use only 1. Operational structure to drive growth 2. Product and marketing initiatives to meet market needs 3. Growing annuity revenue toward a SaaS model (Clinical & Workplace) 4. Strategic relationships with global leaders
Slide 8: 1. Operational Changes to Drive Growth
// 8 1. OPERATIONAL CHANGES TO For personal use only DRIVE GROWTH
Slide 9: Operational Changes to Drive Growth
// 9 1. OPERATIONAL CHANGES TO DRIVE GROWTH • Focus has been on product optimisation, building a solid foundation of large For personal use only customers and creating the right structure for growth: Established revenue model to build annuity revenue Sales model & product to penetrate key markets mo
Slide 10: Strong Operations & Product Development Leaders
// 10 STRONG OPERATIONS & PRODUCT DEVELOPMENT LEADERS • Matt May, former Head of Sales and Operations for Australia, For personal use only promoted to General Manager: • Experienced operations executive and has led dorsaVi’s Australian sales and operations since 2014 • Experience in both clinical an
Slide 11: 2. Product and Marketing Initiatives to Meet Market Needs
// 11 2. PRODUCT AND MARKETING For personal use only INITIATIVES TO MEET MARKET NEEDS
Slide 12: Sales & Marketing Update - Clinical
// 12 SALES & MARKETING UPDATE - CLINICAL • Objectives For personal use only • Remove perceived ‘big decision’ barriers • Shorten sales cycle • Reduce sales involvement • Move devices in higher volume • Build critical mass to allow us to start push/pull marketing • Tactics • Regular campaigns with p
Slide 13: Large Consulting Projects to Self-Managed Monitoring Platform
// 13 LARGE CONSULTING PROJECTS SELF-MANAGED MONITORING PLATFORM For personal use only Data gathered out in the field Centralised Data Employee Manager/Executive
Slide 14: Sales & Marketing Update - Workplace
// 14 SALES & MARKETING UPDATE - WORKPLACE • Objectives For personal use only • Increase awareness in key industries • Leverage existing customer success to accelerate market adoption • Profile industry role models • Increase annuity revenue • Up-sell existing customers (ViSafe to myViSafe) • Tactic
Slide 15: 3. Growing Annuity Revenue Toward SaaS Model
// 15 For personal use only 3. GROWING ANNUITY REVENUE TOWARD SaaS MODEL (Clinical & Workplace)
Slide 16: Clinical Model Is Working
// 16 CLINICAL MODEL IS WORKING For personal use only • All clinical sales now include significant annuity revenue in perpetuity • In the US Clinical market, the combination of reimbursement and cash pay, from the dorsaVi device, provides strong return on investment • Challenges and opportunities •
Slide 17: The US Clinical Market Is Large
// 17 THE US CLINICAL MARKET IS LARGE • >25,000 Orthopaedic surgeons in the USA For personal use only • >60,000 Physical Therapy clinics in the USA 1. Select Medical - 2,000 sites 2. Drayer - 650 sites 3. ATI – 600 sites 4. US PT – 516 sites 5. Athletico – 400 sites 6. Professional PT - 250 sites 7.
Slide 18: Scalable Solutions for Manual Handling
// 18 SCALABLE SOLUTIONS FOR MANUAL HANDLING For personal use only • Strong repeat business from major brands • Self managed solution to monitor employee movement • Trend in moving to annuity model & self managed • Accessible to all organisations with >100 employees • Attractive price point – starti
Slide 19: 4. Strategic Relationships with Global Leaders
// 19 4. STRATEGIC RELATIONSHIPS For personal use only WITH GLOBAL LEADERS
Slide 20: Strategic Relationships to Drive Revenue
// 20 STRATEGIC RELATIONSHIPS TO DRIVE REVENUE For personal use only MAJOR CLINICAL MEDICAL DEVICES PHARMA & RETAIL UNIVERSITIES GROUPS • Large companies with a • Independent evidence on • Appetite for data through • Develop better treatment special interest in how their drugs & the continuum of car
Slide 21: Strategic Relationship Example
// 21 STRATEGIC RELATIONSHIP EXAMPLE • New channel for ViSafe assessments For personal use only • Previously dorsaVi needed to: • identify client • undertake assessment and; • provide the report • AIG to provide ViSafe assessments to key clients • dorsaVi will only provide the data analysis and repo
Slide 22: FY19 Focus
// 22 FY19 FOCUS For personal use only • Focus on clinical growth in the US with Professional Suite • Clinical sales teams to focus more on larger clinical operations with multiple sites • Continued focus on growing annuity in the workplace market • Target strategic partners/channels that give rise
Slide 23: dorsaVi Investor Contact
// 23 dorsaVi INVESTOR CONTACT For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 AU Mobile: +61 417 882 267 US Cell: +1 858 333 9446 ar@dorsaVi.com | dorsaVi.com